TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Sensitivity and specificity of Epistem Genedrive® MTB iD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of MolBio Truenat™ TB Assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Total Score on the Hamilton Anxiety Scale (HAM-A)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pharmacokinetics of RVX000222
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comparison of imaging efficacy for lung cancer lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Readmission with CHF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to TKI Treatment Discontinuation Due to Progressive Disease
Endpoint domain: Mortality/survival
Primary endpoint: Time to TKI Treatment Discontinuation Due to Intolerability
Endpoint domain: Adverse events/effects
Primary endpoint: Time to TKI Treatment Discontinuation Due to Disease Related Death
Endpoint domain: Mortality/survival
Primary endpoint: Safety of Len + Bz
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of allogeneic transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monetary and Food Incentive Delay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of metastatic lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Safety of intravenous ferumoxytol
Endpoint domain: Adverse events/effects
Primary endpoint: Continuous Alcohol Abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Heavy Drinking Days
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Change in Six Minute Walk Test (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biomechanical properties of the carotid arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement of left ventricular diastolic echo variable
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Resolution of Non-alcoholic steatohepatitis (NASH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Minimal Erythema Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: time of fracture healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Lens fluorescence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in urinary transglutaminase 2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: freeze/thaw survival rates of human oocytes
Endpoint domain: Mortality/survival
Primary endpoint: Change in pain score from baseline
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Toxicity and tolerability of dietary flaxseed supplementation
Endpoint domain: Adverse events/effects
Primary endpoint: Change in CSF Amyloid Beta Peptide (Abeta) 42 and Abeta40
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in CSF Abeta42/Abeta40 Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in CSF Tau and Phosphorylated Tau (P-tau) Measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in CogState Battery WM/EF Composite Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Accuracy of POCUS in detecting injuries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Lid Papillae Maximum Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Beta C-terminal telopeptide (B-CTx) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of herbal treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Change in pain degree
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Trough FEV1 on Day 15 of Each Treatment Period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants With Asthma Exacerbations During the Treatment Period
Endpoint domain: Adverse events/effects
Primary endpoint: The incidence of serious complications
Endpoint domain: Adverse events/effects
Primary endpoint: Whole body in vivo glucose turnover
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC 0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in frequency of use of lesu
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Changes in treatment schedules for safety reasons
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of exclusive maternal breastfeeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of MRSA on Repeated Swabs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: ulcerative colitis remission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge and practice regarding BC screening tools
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Small / large bowel transmural enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Chronic Quality of Life (CQOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: R0-Resection according to the tumour classification system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Procedure-Safety (No residual source of radiation)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Fatigue severity scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Normalization of blood concentrations of androgens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Normalization of blood concentrations of prolactin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Normalization of blood concentrations of estrogens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Normalization of blood concentrations of FSH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Normalization of blood concentrations of LH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Thrombus re-evaluation at 48-72 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Thrombus re-evaluation at ~30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Public Health Impact
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient health consequences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients' perceived quality
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Health economy analyses
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Response rate by Tumor Burden Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Appearance or disappearance of lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Area Under the Curve (AUC) of Serum Creatine Kinase Isoenzyme Type Muscle-brain (CK-MB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Acid Reflux
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Related Arousals During Sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgeon Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Patients Using Healthcare Resources
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Patients Taking Sick Leave
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Major complications including catheter-related bloodstream infection
Endpoint domain: Adverse events/effects
Primary endpoint: Functional efficacy
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Complete Remission (CR) + Partial Response (PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monocular Photopic Distance Corrected Intermediate Visual Acuity (DCIVA) at 66 Centimeters (cm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Voriconazole plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of intravenous paracetamol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug urine test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood gas and acid/base status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Investigators Global Assessment Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Absence of Stent Elongation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Successful Stent Deployment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: retina reattachment rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reduction in opium consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability (mRS >3) at discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Joint function improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: incidence rate of neurotoxicity adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: 3D Deviation of the implant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change from baseline score on MDS-UPDRS Part III
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Composite of rate of extension of distal DVT to proximal deep veins or symptomatic PE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Rate of post-thrombotic syndrome (PTS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Prevalence of multi-resistant enterobacteriaceae colonisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Participants achieving Complete Response of Greater Than or Equal to 28 Days Duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BPD Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Fruit and Vegetable Consumption
Endpoint domain: Life impact
Endpoint subdomain: Nutrition
Primary endpoint: standardized body mass index (zbmi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postoperative VAS values
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Cumulative incidence of ICU-acquired colonization related multidrug resistant bacteria
Endpoint domain: Adverse events/effects
Primary endpoint: Polysomnography (quantity & quality of sleep)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of multiple intravenous infusions of MORAb-004
Endpoint domain: Adverse events/effects
Primary endpoint: Consumption of sulfentanil (mean)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MAS (Modified Ashworth Scale) of Wrist Flexor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: root coverage aesthetic score (RES)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Differences in angiographic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Differences in IVUS parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Reaching Targeted INR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Hamstring flexibility change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of blood count results transferred
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Fluorodeoxyglucose (FDG) PET Metabolism (Standard Uptake Value Ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative inguinal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Fugl-Meyer Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target drug-related adverse events (TDRAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Genotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of abnormal haematological parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Refractory inflammatory sacroiliac pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Proportion of men with Grade ≥ 3 adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Next day performance in a standardized test of car driving
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: PSMA-flare after ADT
Endpoint domain: Adverse events/effects
Primary endpoint: Bioimpedance data of wound and intact skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioimpedance data related to local interstitial fluid status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance rate of INR value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Electromyographic Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Muscle strength in the lower extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in cell free plasma DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Cortisol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Testosterone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in cytokine response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in creatine kinase in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Serum Concentrations of Vedolizumab That Helped the Likelihood of Alpha4Beta7 Target Saturation on Day 100 Following Allo-HSCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of allergic bronchial inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Risk of intra-hospital mortality
Endpoint domain: Mortality/survival
Primary endpoint: Frequency of increases in HIV viral load to greater than or equal to 500 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Recognition and management of pre-eclampsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Cardiorrespiratory fitness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functionality assessed with Functional Independence Measure scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Correlation between SIWA and Qol-AD
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proximal tubular natriuresis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean Number of Metaphase II (M-II) Oocytes Retrieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Eye movement performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Communication skills
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Compound score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Ipatasertib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended Phase II Dose (RP2D) of Ipatasertib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical evident thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Asymptomatic central line-associated thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Progression of contrast enhanced cardiac CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Global Myocardial Perfusion During Mental Stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Regional Myocardial Perfusion During Mental Stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Activation of platelet NLRP3 inflammasome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Completion of lab work
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Metabolomic signature changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Patient-Reported Fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Number of Subjects Experiencing a Peri-procedural Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: postoperative respiratory abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: American Shoulder and Elbow Surgeons Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: health-related quality of life of the accompanying parent
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Retinal amyloid protein detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of UP Group Intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility of UP Group Intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Area Under the Plasma Concentration-Time Curve (AUC) of RO5185426
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Concentration (Cmax) of RO5185426
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With a Confirmed and an Unconfirmed Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Infrapatellar Fat Pad Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: 2-years Failure Free Survival (FFS)
Endpoint domain: Mortality/survival
Primary endpoint: Average daily doses of NSAID
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Neonatal Outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fetal Outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Labour and Delivery Outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Psychiatric Readmission
Endpoint domain: Adverse events/effects
Primary endpoint: levels of protein markers (IL-1β, IL-6, IL-8, TNF-α, soluble TNF-receptor 1, angiopoietin-2, sRAGE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Interdevice variability of glucose measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Numerical Rating Scale (PNRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of mental status
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Narcotic requirements equivalents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days in residential treatment
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Use of and relapse to alcohol and illicit drugs
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of decrease in Vitiligo Area Scoring Index (VASI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in thenar oxygenation saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presynaptic Ia inhibition level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes